** Shares of drug developer Replimune Group REPL.O fall 76.5% to $2.90 premarket
** Co says the U.S. FDA declined to approve its experimental skin cancer drug, called RP1, for patients with advanced melanoma
** The FDA, in its so-called complete response letter, said the clinical trial to test the drug "was not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness"
** FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population - REPL
** Co plans to urgently interact with the FDA to find a path forward
** Co was testing RP1 in combination with Bristol Myers Squibb's BMY.N Opdivo in patients with advanced skin cancer
** Up to last close, REPL up 1.8% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。